Alkermes to Present Promising Narcolepsy Treatment Data at Annual Sleep Conference
Alkermes to Present Promising Narcolepsy Treatment Data at Annual Sleep Conference
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
阿爾凱默斯將在SLEEP 2024會議上發佈ALKS 2680的最新臨床數據。
PRNewswire
PRNewswire
– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations –
- 包含全面的從ALKS 2680第Ib期研究的納考1型群組和Vibrance-1第II期研究設計的後期抽象數據已被接受作爲海報展示。
– Findings From In-Depth Qualitative Patient Interviews on the Burden of Narcolepsy Will Also Be Presented –
- 此外，還會呈現局部深度患者面談研究結果，探究急性睡眠發作負擔。
DUBLIN, May 28, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy.
2024年5月28日（美東時間），愛爾凱默斯藥業plc （NASDAQ：ALKS）宣佈計劃在2024年6月1日至5日在休斯敦舉行的第38屆聯盟職業睡眠學會年會上展示與ALKS 2680有關的三個海報。ALKS 2680是該公司正在研發的口服促進睡眠肽二受體（OX2R）激動劑，是一種一日一次的納考症治療新藥。
The company will present two posters during a late-breaking abstract session:
該公司將在後期摘要發言會上展示兩個海報：
- Data from the full cohort (n=10)1 of patients with narcolepsy type 1 (NT1) from the phase 1b, proof-of-concept study evaluating single dose oral administration of ALKS 2680. Safety results and pharmacodynamic efficacy assessments evaluating objective (Maintenance of Wakefulness Test [MWT]) and subjective patient-reported (Karolinska Sleepiness Scale [KSS]) measures of sleepiness will be presented.
- Study design and methods for the Vibrance-1 study, a recently initiated phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with NT1.
- 納考1型患者群體（n=10）接受ALKS 2680一次口服劑量評估的第Ib期初步研究的數據。將呈現安全結果和藥效動力學評估的客觀性（清醒維持測試[MWT]）和主觀患者報告的（卡羅琳卡嗜睡量表[KSS]）標準的嗜睡程度。
- Vibrance-1研究的研究設計和方法，這是一個最近開始的第II期臨床試驗，用於比較ALKS 2680和安慰劑治療納考1型患者的安全性和療效。
In addition, findings from in-depth, qualitative interviews with patients with NT1 (n=12) and narcolepsy type 2 (NT2) (n=10) will be presented. During the 60-minute interviews, participants described the impact and burden of disease on many facets of their lives, including work and school activities, mental health, activities of daily living and relationships.
此外，將呈現與納考1型（n=12）和納考2型（n=10）患者進行的深度定性面談的結果。在60分鐘的面談中，參與者描述了疾病對其生活的許多方面產生的影響和負擔，包括工作和學校活動、心理健康、日常生活活動和人際關係。
譯文內容由第三人軟體翻譯。